SEC Form 4 · accession 0001140361-17-011981
ARDELYX, INC. · ARDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David P. Rosenbaum
Officer — SVP, Drug Development
Period of report
Mar 10, 2017
Accepted (ET)
Mar 14, 2017 · 8:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001437402
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Mar 10, 2017 | S | 1,000 | $13.4823 | D | 1,277 | I | See Footnote |
| Common StockF4 | holding | — | — | — | 42,180 | D | ||
| Common StockF5 | holding | — | — | — | 77,592 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 364 shares acquired under the Issuer's Employee Stock Purchase Plan on February 28, 2017.
- F2Consists of 1,277 shares acquired under the Issuer's Employee Stock Purchase Plan on February 28, 2017.
- F3The shares are directly held by the Reporting Person's wife.
- F4Includes (i) 2,051 shares acquired under the Issuer's Employee Stock Purchase Plan on February 28, 2017 and (ii) 17,985 restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof.
- F5The shares are directly held by David Paul Rosenbaum and Susan Edelstein Rosenbaum, Trustees of the David Paul Rosenbaum Family Trust.